Document:

EX-10.4

 Exhibit 10.4 
 EMPLOYMENT AGREEMENT 
 This EMPLOYMENT AGREEMENT
(“Agreement”) made effective as of July 17, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Russell Pagano (the “Executive”). 

In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows: 

1. Employment. The Company agrees to employ the Executive and the Executive agrees to be employed by the Company as Vice
President, Regulatory & Clinical Affairs and to be responsible for the typical management responsibilities expected of an employee holding such position and such other responsibilities customarily pertaining to such position as may be
assigned to Executive from time to time by the Chief Executive Officer of the Company or such other executive of the Company to whom the Executive might directly report to, all for the Period of Employment as provided in Section 2 below and
upon the terms and conditions provided in the Agreement. 
 2. Term. The period of Executive’s employment under this
Agreement, will commence on July 17, 2012 , and shall continue for a period of two (2) years through July 16, 2014, subject to extension or termination as provided in this Agreement (“Period of Employment”). Any expiration
or termination of this Agreement shall not affect the term of the Indemnification Agreement dated May 23, 2007 (“Indemnification Agreement”) and the Confidential Information and Inventions Agreement dated May 3, 2007
(“Confidential Information and Inventions Agreement”) between the Parties. To the extent that Executive’s employment continues following the expiration and nonrenewal of this Agreement, the Executives employment shall continue
at-will, however Executive’s rights with respect to Without Cause Termination shall continue to the extent set forth in Section 8. 
 3. Duties. During the Period of Employment, the Executive shall devote their full business time, attention and skill to the business and affairs of the Company and its Affiliates. The Executive
will perform faithfully the duties that may be assigned to him from time to time in accordance herewith by the Chief Executive Officer of the Company or such other executive of the Company to whom the Executive might directly report to. 

4. Compensation. For all services rendered by the Executive in any capacity during the Period of Employment, the Executive shall
be compensated as follows: 
 (a) Base Salary. The Company shall pay the Executive an annual base salary
of $244,800 (“Base Salary”). Base Salary shall be payable according to the customary payroll practices of the Company but in no event less frequently than twice each month. The Base Salary shall be reviewed each fiscal period and shall be
subject to increase according to the policies and practices adopted by the Company from time to time. 
 (b)
Incentive Compensation Award. The Executive shall also be eligible to receive annual incentive bonuses consisting of cash and/or options to purchase Company common stock consistent with annual incentive awards for other members of the senior

 
management team. The payment of such bonuses shall be based on the performance and satisfaction of specific milestones mutually agreed upon by the Chief Executive Officer (or such other executive
of the Company to whom the Executive might directly report to) and the Executive, and shall be further based upon the Executive’s performance as evaluated by the Chief Executive Officer or such other executive of the Company to whom the
Executive might directly report to. In no event shall the payment of any annual incentive bonus to the Executive be made later than March 15 of the calendar year next following the calendar year during which such annual incentive bonus is
earned. 
 (d) Additional Benefits. The Executive will be entitled to participate in all employee benefit
plans or programs and receive all benefits and perquisites for which any salaried employees are eligible under any existing or future plan or program established by the Company or its affiliates and available to similarly situated employees of the
Company, including participation in stock option plans. The Executive may participate to the extent permissible under the terms and provisions of such plans or programs. These may include group hospitalization, health, dental care, life or other
insurance, sick leave plans, travel or accident insurance and disability insurance. Nothing in this Agreement will preclude the Company or Company affiliates from amending or terminating any of the plans or programs applicable to salaried employees
or senior executives as long as the total value of all benefits is not materially decreased. The Executive will be entitled to annual paid time off, consistent with the Company’s paid time off policy and Company holidays as determined by the
Company. The Company will provide Executive with sufficient equipment, supplies and resources to accomplish their duties and will purchase and/or reimburse Executive for the cost of maintaining preapproved professional memberships. 

5. Business Expenses and Other Expenses. The Company will reimburse the Executive for all reasonable travel and other expenses
incurred by the Executive in connection with the performance of their duties and obligations under this Agreement. 
 6.
Disability. 
 (a) In the event of disability of the Executive during the Period of Employment, the
Company will continue to pay the Executive according to the compensation provisions of this Agreement during the period of the disability, until such time as any long term disability insurance benefits accruing to the Executive are available.
However, in the event the Executive is disabled for twelve (12) weeks (consecutive or nonconsecutive) during any twelve (12) month period, the Company may terminate the employment of the Executive. In this case, normal compensation will
cease, except for earned but unpaid Base Salary and, effective as of his termination date, the Executive shall be entitled to receive salary continuation for a period of six (6) months thereafter, to be paid in substantially equal installments
in accordance with the Company’s regular payroll practices applicable to similarly situated active employees and determined by reference to his Base Salary as in effect on the day immediately prior to his termination date. 

(b) During the period the Executive is receiving payments of either regular compensation or disability insurance described
in this Agreement and to the extent reasonable considering the Executive’s disability, the Executive will furnish information and 

  
 2 

 
assistance to the Company and from time to time will make themselves available to the Company to undertake assignments consistent with their prior position with the Company. If the Company fails
to make a payment or provide a benefit required as part of the Agreement, the Executive’s obligation to furnish information and assistance will end. 
 (c) For purposes of this Agreement, the Executive will be considered to be “disabled” if he satisfies the requirements necessary to receive benefits under the Company’s long-term disability
plan or, in the absence of any such plan, under any insurance policy providing benefits for long-term disabilities that is procured for the Executive pursuant to this Agreement or otherwise. 

7. Death. In the event of the death of the Executive during the Period of Employment, the Company’s obligation to make
payments under this Agreement shall cease as of the date of death, except for earned but unpaid Base Salary. 
 8. Effect of
Termination of Employment. 
 (a) If the Executive’s employment terminates due to a Without Cause
Termination, as defined below, the Company will provide the Executive six (6) months’ Base Salary as in effect at the time of the termination on the Company’s regular payroll dates for such Base Salary. Additionally, the benefits and
perquisites described in this Agreement as in effect at the date of termination of employment will be continued for six (6) months to the extent permissible under the law and consistent with the tax status of such benefit plans. Amounts that
the Company is obligated to pay hereunder, including amounts paid by the Company to third parties to maintain benefit and perquisites, shall be less any amount the Executive receives from a third party for services provided as an employee,
consultant, agent or the like, including any cash or non-cash consideration such as stock or stock options. Subject to Section 12 below, the salary continuation payments described in this Section 8 will commence within fourteen
(14) days of the Company’s receipt of the Executive’s executed general release of claims under Section 8(b) of this Agreement, and to the extent permissible under Section 12 below, such salary continuation payments shall be
made retroactive back to the date the Executive’s employment with the Company terminates. 
 (b) All
severance compensation provided for herein shall be expressly conditioned upon the Executive’s execution, delivery, and non-revocation of a general release of claims in the form set forth as Exhibit A, hereto. All severance compensation
provided for herein shall be further expressly conditioned upon the Executive complying with all post-employment obligations set forth herein and set forth in the Indemnification Agreement and the Confidential Information and Inventions Agreement.

 (c) If the Executive’s employment terminates due to Termination for Cause (as defined below), breach of
this Agreement by Executive or resignation by Executive, earned but unpaid Base Salary will be paid on a pro-rated basis for the year in which the termination occurs. No other payments will be made or benefits provided by the Company. 

  
 3 

 (d) For this Agreement, the following terms have the following meanings:

 (i) “Termination for Cause” means termination of the Executive’s employment by the
Company’s Chief Executive Officer or Board of Directors acting in good faith by the Company by written notice to the Executive specifying the event relied upon for such termination, due to the Executive’s willful misconduct with respect to
their duties under this Agreement, including but not limited to conviction for a felony or a common law fraud that results in or is likely to result in economic damage to the Company. 

(ii) “Without Cause Termination” means “constructive termination” or actual termination of the
Executive’s employment other than due to death, disability, Termination for Cause, or resignation by Executive. Constructive Termination shall occur upon Executive’s resignation as a result of either of the following trigger events:
(A) a significant change to job scope or job responsibilities, (B) a relocation of Company headquarters of more than 50 miles, or (C) the expiration of this Agreement in the absence of a renewal, extension, or superseding Agreement;
provided that the Executive gives the Company notice of such Constructive Termination within ninety (90) days of such trigger event, and the Company fails to cure such trigger event within thirty (30) days of such notice of Constructive
Termination and such resignation is effective within sixty (60) days of expiration of the Company’s thirty (30) day cure period. 
 9. Other Duties of the Executive during and after the Period of Employment. 
 (a) The Executive will, with reasonable notice during or after the Period of Employment, furnish information as may be in their possession and cooperate with the Company as may reasonably be requested in
connection with any claims or legal actions in which the Company is or may become a party. 
 (b) The Executive
recognizes and acknowledges that all non-public information pertaining to the affairs, business, clients, customers or other relationships of the Company is confidential and is a unique and valuable asset of the Company. Access to and knowledge of
this information are essential to the performance of the Executive’s duties under this Agreement. The Executive will not during the Period of Employment and for 36 months thereafter except to the extent reasonably necessary in performance of
the duties under this Agreement, or as required by law, give to any person, firm, association, corporation or governmental agency any non-public information, including but not limited to information relating to the affairs, business, clients,
customers, technology or other relationships of the Company and any Confidential Information as that term is defined in the Confident Information and Inventions Agreement. The Executive will not make use of such information for his own purposes or
for the benefit of any person or organization other than the Company. All records, memoranda, etc., relating to the business of the Company, whether made by the Executive or otherwise coming into his possession, are confidential and will remain the
property of the Company. Confidential information shall not include information that (i) becomes generally available to the public other than as a result of disclosure by the Executive, (ii) was available to the Executive on a
non-confidential basis prior to disclosure to the Executive in connection with his duties to the Company, provided that the source of such information is not known to the Executive to be bound by a

  
 4 

 
confidentiality agreement or other contractual obligation of confidentiality to the Company or (iii) becomes available to the Executive on a non-confidential basis from a source other than
the Company (or any agent, employee or affiliate of Company) provided such source is not known to the Executive to be bound by a confidentiality agreement or other contractual obligation of confidentiality to the Company. 

(c) During the Period of Employment, the Executive will not use his status with the Company to obtain loans, goods or
services from another organization on terms that would not be available to him in the absence of his relationship to the Company. During the period of his employment and for a period of 12 months thereafter, the Executive will not directly or
indirectly manage, consult or work for, serve as employee, officer, director, consultant, agent or subcontractor for, finance, or own any part of or exercise management control over any business or entity wherein the Executive is directly or
indirectly engaged in the development and/or commercialization of a Competitive Product. A “Competitive Product” shall mean any product intended for use in orthopedics, that contains recombinant platelet-derived growth factor, recombinant
insulin-like growth factor, or any recombinant osteoinductive protein, including bone morphogenetic proteins or any product containing any other protein intended to be used for tissue repair or regeneration. In addition, during such 12 month period
Executive will not engage, directly or indirectly, in any business activity or enterprise which is a “Competitive Activity”. For purposes hereof, “Competitive Activity” means the making of investments in or the provision of
capital to any enterprise (or an Affiliate), or to any person in connection with any enterprise (or an Affiliate thereof), with respect in which the Company has invested or provided capital or proposed, in writing, to invest or provide capital
during the term of the Executive’s employment, or to pursue any similar investment opportunity with any individual or enterprise introduced to the Executive or Company directly in connection with the performance of the Executive’s duties
to the Company during the term of his employment, in each case in the area of tissue repair or regeneration. For purposes of this restriction, the receipt of stock, stock options or restricted stock for any reason (including as consideration for
services or otherwise) shall be deemed an investment in the issuing company or any Affiliates thereof. This restriction shall not apply to any investment opportunity that has been declined by the Company. “Affiliate” shall mean any
company, corporation, business or entity that is controlled by, controlling, or under common control with a company. The Executive acknowledges that the covenants contained herein are reasonable as to geographic and temporal scope. For a twelve
month period after termination of the Period of Employment for any reason, the Executive will not solicit to hire any employee of the Company or solicit any employee to leave the employ of the Company. 

(d) After the Period of Employment, upon reasonable notice the Executive shall provide the Company with sufficient
information to verify compliance with his post-employment obligations hereunder, including providing periodic reports detailing any compensation received from another party during the severance period outlined above, and promptly responding to
specific requests from the Company regarding possible violations of any restrictive covenant hereunder or under any other agreement with the Company. 
 (e) The Executive acknowledges that the breach or threatened or attempted breach of any provision of Section 9 would cause irreparable harm to the Company not

  
 5 

 
compensable in monetary damages and that the Company shall be entitled, in addition to all other applicable remedies, to a temporary and permanent injunction and a decree for specific performance
of the terms of Section 9 without being required to prove damages or furnish any bond or other security. 

(f) The Executive shall not be bound by the provisions of Section 9 in the event of the default by the Company in its
obligations under this Agreement that are to be performed upon or after termination of this Agreement, provided that such default is not cured by the Company within sixty (60) days of the Company’s receipt from the Executive of a written
notice of default. 
 (g) For purposes of Section 9, the “Company” shall include any person or
entity that, directly or indirectly, controls or is controlled by the Company or is under common control with the Company. 

10. Indemnification; Litigation. 
 The Executive and the Company previously entered into the Indemnification Agreement under which the Company has agreed to indemnify the Executive from and against certain liability associated with his
providing services as an executive of the Company. The parties hereby reaffirm the Indemnification Agreement, which shall remain effective together with this Employment Agreement. In the event of a conflict between this Agreement and the
Indemnification Agreement, the Indemnification Agreement shall supersede this Agreement. 
 11. Effect of Change in
Control. 
 (a) In the event there is a Change in Control (as defined below) and in connection with such
event or within the twelve (12) month period following such event Executive is terminated in a Without Cause Termination, or Executive elects to resign upon written notice to the Company following an event that constitutes Good Reason (as
defined below), all outstanding stock options, restricted stock, restricted stock units, and any other unvested equity incentives shall become fully exercisable and vested as of the effective date of such termination or resignation and shall remain
exercisable for their full stated terms. In addition, the Company shall pay Executive upon such termination or resignation, in exchange for the Executive complying with the obligations and restriction set forth or referred to in Section 8, the
severance payments and benefits due under Section eight (8)(a) above with respect to a Without Cause Termination, but such payments and benefits shall be provided for a period of twelve (12) months following termination or resignation
pursuant to this Section. 
 (b) A “Change in Control” shall be deemed to have occurred if (i) a
tender offer shall be made and consummated for the ownership of more than fifty percent (50%) of the outstanding voting securities of the Company, (ii) the Company shall be merged or consolidated with another corporation or entity and as a
result of such merger or consolidation less than fifty percent (50%) of the outstanding voting securities of the surviving or resulting corporation or entity shall be owned in the aggregate by the former shareholders of the Company, as the same
shall have existed immediately prior to such 

  
 6 

 
merger or consolidation, (iii) the Company shall sell all or substantially all of its assets to another corporation or entity which is not a wholly-owned subsidiary, or (iv) a person,
within the meaning of Section 3(a)(9) or of Section 13 (d)(3) (as in effect on the date hereof) of the Securities and Exchange Act of 1934 (“Exchange Act”), shall acquire more than fifty percent (50%) of the outstanding
voting securities of the Company (whether directly, indirectly, beneficially, or of record). For purposes hereof, ownership of voting securities shall take into account and shall include ownership as determined by applying the provisions of Rule
13d-3(d)(1)(i) (as in effect on the date hereof) pursuant to the Exchange Act. 
 (c) A resignation for
“Good Reason” shall be deemed to have occurred if the Executive resigns his employment with the Company after the occurrence of any of the following events, to which the Executive has not expressly consented in writing: (i) a material
reduction in the Executive’s Base Salary (other than one applicable to all senior management); (ii) a material reduction in job duties, authority, responsibilities and requirements inconsistent with the Executive’s position with the
Company and the Executive’s prior duties, authority, responsibilities, and requirements or a change in the Executive’s reporting relationship; (iii) a relocation of the Executive to a facility or location more than fifty
(50) miles from the address of the Company’s headquarters office as of the effective date of this Agreement, or (iv) material breach by the Company of any of the material covenants herein. Any of the foregoing conditions described in
this Section 11(c) will constitute “Good Reason” only if the Executive first delivers a notice of termination to the Company identifying such condition (or conditions) within ninety (90) days after the initial occurrence of such
condition (or conditions) and such condition continues uncured for a period of thirty (30) days after the delivery of such notice of termination. Notwithstanding the foregoing, the Executive’s termination of employment will not be
considered to be for Good Reason unless the Company fails to cure such condition and such termination of employment occurs within sixty (60) days of the expiration of the Company’s (30) day cure period. 

(d) Notwithstanding anything to the contrary in Section 11, if payment of all severance payments and benefits under
Section 11(a) above (the “CIC Severance Benefits”) would, together with any other payments and benefits payable to or for the benefit of the Executive in connection with the Change in Control (together with the CIC Severance
Benefits,” the “CIC Benefits”), subject the Executive to tax under Code Section 4999, and if a reduction in the amount of the CIC Severance Benefits would result in the amount of the CIC Benefits, net of all federal and state
income taxes on the CIC Benefits (calculated at the highest marginal rates) and any taxes on the CIC Benefits under Code Section 4999 (such amount, the “Net After-Tax Receipts”), being equal to or greater than the Net After-Tax
Receipts that would result from payment of the CIC Severance Benefits without reduction, then the aggregate amount of the CIC Severance Benefits shall be reduced to the smallest amount that results in the Net After-Tax Receipts being equal to or
greater than the Net After-Tax Receipts that would result if the CIC Severance Benefits were reduced to any other amount. Any such reduction shall be implemented first by reducing the period during which the Executive continues to receive his Base
Salary, then by reducing the amount of any other CIC Severance Benefits payable in cash, and only thereafter by reducing the period during which other benefits and perquisites are provided. 

  
 7 

 Unless the Company and the Executive otherwise agree in writing, any
determination required under this Section 11(d) will be made in writing by the Company’s independent public accountants or such other person or entity to which the parties mutually agree (the “Firm”), whose determination will be
conclusive and binding upon the Executive and the Company. For purposes of making the calculations required by this Section 11(d), the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on
reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a
determination under this Section. The Company will bear all costs the Firm may incur in connection with any calculations contemplated by this Section 11(d). 
 12. Tax Provisions. 
 (a) Notwithstanding any other
provision of this Agreement whatsoever, the Company shall have the right, after consulting with and securing the approval of the Executive (which approval shall not unreasonably be withheld), to provide for the application and effects of
Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (relating to deferred compensation arrangements) and any related regulatory or administrative guidance issued by the Internal Revenue Service such that the
severance and other benefits provided under this Agreement shall not trigger the additional tax, interest, and any related penalties imposed by Code Section 409A(l)(B). Although the Company intends to administer the Agreement so that it will
comply with the requirements of Code Section 409A, the Company does not represent or warrant that the Agreement will comply with Code Section 409A or any other provision of federal, state, local or non-United States law. Neither the
Company, its subsidiaries, nor their respective directors, officers, employees or advisers will be liable to the Executive (or any other individual claiming a benefit through the Executive) for any tax, interest, or penalties the Executive may owe
as a result of compensation paid under the Agreement, and the Company and its subsidiaries will have no obligation to indemnify or otherwise protect the Executive from the obligation to pay any taxes pursuant to Code Section 409A. 

(b) The Company shall delay the payment of any severance benefits payable under this Agreement as required to comply with
Code Section 409A(a)(2)(B)(i) (relating to payments made to certain “specified employees” of certain publicly-traded companies) and in such event, any such amount to which the Executive would otherwise be entitled during the six
(6) month period immediately following his termination of employment shall instead be accumulated through and paid or provided on the first business day following the expiration of such six (6) month period, or if earlier, the date of his
death. For the avoidance of doubt, no portion of any such severance benefits shall be subject to the foregoing delay if and to the extent that such benefits (i) constitute a “short term deferral” within the meaning of
Section 1.409A-1(a)(4) of the Treasury Regulations, or (ii) (A) are being paid due to the Executive’s “involuntary separation from service” (within the meaning of Section 1.409A-1(n)

  
 8 

 
of the Treasury Regulations); (B) do not exceed two times the lesser of (1) the Executive’s annualized compensation from the Company for the calendar year prior to the calendar
year in which the termination occurs, or (2) the maximum amount that may be taken into account under a qualified plan pursuant to Code Section 401(a)(17) for the year in which the Executive’s employment terminates; and (C) the
payment is required under this Agreement to be paid no later than the last day of the second (2nd) calendar year following the calendar year during which the Executive’s “separation from service” (within the meaning of Code
Section 409A) occurs. For purposes of Code Section 409A, the Executive’s right to receive installment payments pursuant to any provision in this Agreement shall be treated as a right to receive a series of separate and distinct
payments. The determination of whether the Executive is a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i) as of the time of his termination of employment shall made by the Company in accordance with the terms of
Code Section 409A and the applicable guidance thereunder (including without limitation Treasury Regulation Section 1.409A-1(i) and any successor provision thereto). 

(c) The continued employee benefits available under Sections 8 and 11 above that are taxable benefits (and that are not
disability pay or death benefit plans within the meaning of Code Section 409A) are intended to comply, to the maximum extent possible, with the exception to Code Section 409A set forth in Section 1.409A-1(b)(9)(v) of the Treasury
Regulations (and any successor thereto). To the extent that any of those benefits either do not qualify for that exception, or are provided beyond the applicable time periods set forth in Section 1.409A-1(b)(9)(v) of the Treasury Regulations,
then such amounts will be reimbursed or provided no later than December 31 of the year following the year in which the expense was incurred and will be subject to the following additional rules: (i) the amount of in-kind benefits provided,
during any calendar year shall not affect the amount of in-kind benefits to be provided, during any other calendar year; and (ii) the right to in-kind benefits shall not be subject to liquidation or exchange for another benefit. 

(d) For the avoidance of doubt, no amount subject to the requirements of Code Section 409A shall become payable to
the Executive as a result of a termination of employment that does not constitute a “separation from service” within the meaning of Code Section 409A(a)(2)(A)(i) and Section 1.409A-1(h) of the Treasury Regulations. 

13. Consolidation; Merger or Sale of Assets. Nothing in this Agreement shall preclude the Company from consolidating or merging
into or with, or transferring all or substantially all of its assets to, another corporation that assumes this Agreement and all obligations and undertakings of the Company hereunder. Upon such a consolidation, merger or sale of assets, the term
“the Company” as used will mean the other corporation and this Agreement shall continue in full force and effect. 

14. Modification. This Agreement may not be modified or amended except in writing signed by the parties. No term or condition of
this Agreement will be deemed to have been waived, except in writing by the party charged with waiver. A waiver shall operate only as to the specific term or condition waived and will not constitute a waiver for the future or act on anything other
than that which is specifically waived. 

  
 9 

 15. Governing Law. This Agreement has been executed and delivered in the State of
Tennessee and its validity, interpretation, performance and enforcement shall be governed by the laws of that state. 
 16.
Notices. All notices, requests, consents and other communications hereunder shall be in writing and shall be deemed to have been made when delivered or mailed first-class postage prepaid by registered mail, return receipt requested, or when
delivered if by hand, overnight delivery service or confirmed facsimile transmission, to the following: 
 (a) If
to the Company, to: 
 Chief Executive Officer 
 BioMimetic Therapeutics, Inc. 
 389 Nichol Mill Lane 

Franklin, TN 37067 
 with a copy to: 
 Legal Department 

BioMimetic Therapeutics, Inc. 
 389 Nichol Mill Lane 
 Franklin, TN 37067 

or at such other address as may have been furnished to the Executive by the Company in writing; or 

(b) If to the Executive, at: 653 Aylesford Lane, Franklin, TN 37069, or such other address as may have been furnished to
the Company by the Executive in writing. 
 17. Entire Agreement. This Agreement, together with the Indemnification
Agreement and the previously executed Confidential Information and Inventions Agreement constitute the entire agreement between the Parties as to the subject matter hereof, and all prior negotiations, representations, agreements and understandings
are merged into, extinguished by and completely expressed by this Agreement. In the event of a conflict between this Agreement and the Confidential Information and Inventions Agreement, this Agreement shall supersede the Confidential Information and
Inventions Agreement. In the event of a conflict between this Agreement and the Indemnification Agreement, the Indemnification Agreement shall supersede this Agreement. 
 18. Binding Agreement. This Agreement shall be binding on the parties’ successors, heirs and assigns. 
 [Signature Page to Follow.] 

  
 10 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
the 17th day of July 2012. 

 

	
	RUSSELL PAGANO
	
	 /s/ Russell Pagano

 

			
	BIOMIMETIC THERAPEUTICS, INC.
		
	By:	 	 /s/ Samuel E. Lynch

		 	Samuel E. Lynch
		 	President and Chief Executive Officer

 Signature Page to Employment AgreementEX-10.5

 Exhibit 10.5 
 Amendment to Employment Agreement 
 THIS AMENDMENT TO EMPLOYMENT AGREEMENT
(this “Amendment”) is made and entered into as of November 18, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Samuel Lynch. 

WITNESSETH 
 WHEREAS, there parties hereto entered into an employment agreement, dated as of July 17, 2009 (the “Employment Agreement”); 

WHEREAS, each party wishes to amend the Employment Agreement to modify certain terms and conditions with respect to the benefits
of the Executive in connection with a change of control; 
 NOW, THEREFORE, for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Executive hereby agree as follows: 
 1.
Addition of Section 12(e) to the Employment Agreement. The following is hereby added to the Employment Agreement as a new Section 12(e): 
 “(e) Notwithstanding anything to the contrary in this Agreement, if the payments and benefits payable under this Agreement (the “Benefits”) would, together with any other payments and
benefits payable to or for the benefit of the Executive in connection with a Change in Control (together with the Benefits, the “CIC Benefits”), subject the Executive to tax under Code Section 4999, and if a reduction in the amount of
the CIC Benefits would result in the amount of the CIC Benefits, net of all federal and state income taxes on the CIC Benefits (calculated at the highest marginal rates) and any taxes on the CIC Benefits under Code Section 4999 (such amount,
the “Net After-Tax Receipts”), being equal to or greater than the Net After-Tax Receipts that would result from payment of the CIC Benefits without reduction, then the aggregate amount of the CIC Benefits shall be reduced to the smallest
amount that results in the Net After-Tax Receipts being equal to or greater than the Net After-Tax Receipts that would result if the CIC Benefits were reduced to any other amount. Any such reduction shall be implemented first by reducing CIC
Benefits denominated and payable in cash (other than CIC Benefits that are permitted to be valued under Treasury Regulation section 1.280G-1, Q/A-24(c), such as certain equity-based compensation (“Section 24(c) Payments”)), then by
reducing CIC Benefits payable in-kind or by reimbursement, and only thereafter by reducing or eliminating Section 24(c) Payments. 
 Unless the Company and the Executive otherwise agree in writing, any determination required under this Section 12(e) will be made in writing by the Company’s independent public accountants or
such other person or entity to which the parties mutually agree (the “Firm”), whose determination will be conclusive and binding upon the Executive and the Company. For purposes of making the calculations required by this
Section 12(e), the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the
Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section. The Company will bear all costs the Firm may incur in connection with any calculations
contemplated by this Section 12(e).” 

 2. Miscellaneous Provisions. 

2.1 Counterparts. This Amendment may be executed in two counterparts, each of which shall be deemed an original but both of which
together shall constitute one and the same instrument. 
 2.2 Governing Law. This Amendment shall be governed by, and
construed in accordance with, the law of the State of Tennessee without giving effect to any choice or conflict of law provision or rule (whether of the State of Tennessee or any other jurisdiction) that would cause the application of the laws of
any jurisdiction other than the State of Tennessee. 

  
 2 

 IN WITNESS WHEREOF, each of the undersigned has executed this Amendment as an agreement
under seal as of the date first above written. 
  

			
		 	 EXECUTIVE

		
		 	 /s/ Dr. Samuel E. Lynch

		 	Dr. Samuel E. Lynch
		
		 	BIOMIMETIC THERAPEUTICS, INC.
		
		 	 /s/ Larry Bullock 

		 	Name: Larry Bullock
		 	Title: Chief Financial Officer

 [Signature Page to Amendment to Employment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]